Skip to main content

CORRECTION article

Front. Pharmacol., 05 September 2022
Sec. Translational Pharmacology
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1014363

Corrigendum: Triglyceride-mimetic prodrugs of buprenorphine enhance oral bioavailability via promotion of lymphatic transport

This article is a correction to:

  1. Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport

    1. Read original article
Tim Quach&#x;&#x;Tim Quach1†‡Luojuan Hu&#x;Luojuan Hu2‡Sifei Han Sifei Han2*Shea F. LimShea F. Lim1Danielle SenyschynDanielle Senyschyn2Preeti YadavPreeti Yadav2Natalie L. TrevaskisNatalie L. Trevaskis2Jamie S. Simpson&#x;Jamie S. Simpson1†Christopher J. H. Porter Christopher J. H. Porter2*
  • 1Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
  • 2Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia

A Corrigendum on
Triglyceride-mimeticprodrugs of buprenorphine enhance oral bioavailability via promotion of lymphatic transport

by Quach T, Hu L, Han S, Lim SF, Senyschyn D, Yadav P, Trevaksis NL, Simpson JS and Porter CJH (2022). Front. Pharmacol. 13:879660. doi: 10.3389/fphar.2022.879660

In the published article, an author name was incorrectly written as Trevaksis. The correct spelling is Trevaskis.

Note this error is repeated in the main heading and in the citation information on page 1. It is also incorrect in the Copyright statement.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: lymphatic transport, prodrug, triglyceride mimetic, buprenorphine, first-pass metabolism, oral bioavailability, opioid analgesics

Citation: Quach T, Hu L, Han S, Lim SF, Senyschyn D, Yadav P, Trevaskis NL, Simpson JS and Porter CJH (2022) Corrigendum: Triglyceride-mimetic prodrugs of buprenorphine enhance oral bioavailability via promotion of lymphatic transport. Front. Pharmacol. 13:1014363. doi: 10.3389/fphar.2022.1014363

Received: 08 August 2022; Accepted: 09 August 2022;
Published: 05 September 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Quach, Hu, Han, Lim, Senyschyn, Yadav, Trevaskis, Simpson and Porter. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Sifei Han, sifei.han@monash.edu; Christopher J. H. Porter, chris.porter@monash.edu

†Present address: Tim Quach and Jamie S. Simpson, PureTech Health, Boston, MA, United States

‡These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.